Barclays lifts BioMarin Pharmaceutical stock target to USD 114.00

Published on 10/15/2026 at 21:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue in the second quarter of 2026 was USD 989.71 million, up 20.00 percent. BioMarin Pharmaceutical stock costs EUR 50.29 on October 15, 2026.

Analyst target and earnings date

Barclays raised its BioMarin target from USD 111.00 to USD 114.00 on October 14, 2026.
Revenue in the second quarter of 2026 reached USD 989.71 million, up 20.00 percent year over year.
BioMarin Pharmaceutical stock costs EUR 50.29 at Lang & Schwarz on October 15, 2026 at 9:39 p.m. CEST.
BioMarin is estimated to report third-quarter results on October 26, 2026.

BMRN, US09061G1013, Illustration mit AI erstellt.

Barclays raised its BioMarin Pharmaceutical target to USD 114.00 from USD 111.00 on October 14, 2026, while keeping an Overweight rating, according to Markets Insider. The target is 101.79 percent above the Nasdaq price of USD 56.49 at 3:45 p.m. ET on October 15, 2026. BioMarin Pharmaceutical stock was trading at EUR 50.29 at Lang & Schwarz on October 15, 2026 at 9:39 p.m. CEST.

Second-quarter revenue reached USD 989.71 million

BioMarin reported revenue of USD 989.71 million in the second quarter of 2026, up 20.00 percent from the year-ago quarter, according to MarketBeat. The company also recorded USD 1.20 in earnings per share, exceeding the USD 0.95 consensus estimate by USD 0.25. The figures give the analyst target a recent operating reference, although earnings per share were below the USD 1.44 reported for the same quarter a year earlier.

Range and valuation shape the picture

BioMarin's Nasdaq share price stood within a USD 49.26 to USD 70.98 52-week range as of October 15, 2026. The company had a market capitalization of USD 10.9 billion, a price-to-earnings ratio of 144.54, volume of 1,857,035 shares and average volume of 2,100,345 shares on the same date.

BioMarin disclosed on October 6, 2026 that the Alesta acquisition was expected to create a USD 283 million pretax acquired in-process research and development charge in the third quarter. The filing also projected a USD 1.50 negative impact on both GAAP and non-GAAP diluted earnings per share for that quarter, according to SEC.

October 26 results set the next date

BioMarin is estimated to report third-quarter 2026 results after the market close on October 26, 2026, with a conference call scheduled for 4:30 p.m. ET. MarketBeat lists consensus estimates of USD 1.35 in earnings per share and USD 1.02 billion in revenue for that quarter, compared with USD 0.12 and USD 776.13 million in the year-ago quarter.

Comparison with peers

BMRN (Nasdaq, USD): P/E 144.54, market capitalization USD 10.9 billion

Vertex Pharmaceuticals (Nasdaq, USD): plus 1.91 percent, P/E 29.59, market capitalization USD 128.8 billion

Regeneron Pharmaceuticals (Nasdaq, USD): plus 2.73 percent, P/E 19.76, market capitalization USD 82.3 billion

Price stays below the yearly high

The euro quotation gives German investors a separate view of the Nasdaq-listed company, while the reported target, upcoming results and third-quarter charge define the next valuation checkpoints.

BioMarin Pharmaceutical stock was trading at EUR 50.29 at Lang & Schwarz on October 15, 2026 at 9:39 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of BioMarin Pharmaceutical stock.